Shandong Xinbo invites Dr. Yuan Shoujun to give an academic lecture on "Belt and Road Model: Breaking the Industry Pain Points of Multi drug Joint Evaluation and Supporting Drug Interaction Evaluation
2023/05/17
Many serious diseases, such as cancer, have complex causes and belong to multi-target diseases. Combination therapy targeting multiple targets is easier to achieve treatment goals than single target therapy. The combination of drugs can generate multi-level interactions, ultimately manifested as synergistic, additive, or antagonistic effects. The prerequisite for quantitatively evaluating it is to obtain the expected additive effect value of the combination of multiple drugs. However, for a long time, there has been a lack of reliable methods for accurately calculating synergy, addition, and antagonism, which has hindered the development of new compound drug research.
Dr. Yuan Shoujun discovered the mathematical law of the expected additive effect of multi drug combination through equivalent dose exchange and the introduction of the sequential and set principles of pharmacological effects, abbreviated as the "Belt and Line" method.
On May 16, 2023, Shandong Xinbo Pharmaceutical R&D Co., Ltd. invited Dr. Yuan Shoujun to give an academic lecture.
Dr. Yuan Shoujun gave an in-depth explanation of the "Belt and Road Model" and combined it with practical cases. Colleagues present also had active interactions.
- Pre:Shandong Xinbo was invited to participate in the first National Experimental Pathology High end Medical Device Innovation Forum
- Next:Shandong Xinbo was invited to attend the Chinese Society of Toxicology Conference on Drug Toxicology and Safety Evaluation (2023) and the Second Summit Forum of the Biomedical Industry in the Guangdon